Stay current on the latest developments from agencies including the CFPB, Federal Reserve, FDIC, and OCC to advise clients on real-life regulatory situations.
Rite Aid Corp. said March 29 that its bid for Albertsons Companies is near the finish line, after clearing the U.S. merger review process.
The transaction, announced last month, won early termination of waiting period requirements under the Hart-Scott-Rodino Act, Rite Aid said.
While the deal was expected to go through, the speed of the process is a little surprising given potential antitrust risks, David Balto, a Washington antitrust attorney and former Federal Trade Commission policy director, told Bloomberg Law.
“There were clearly significant overlaps in some metropolitan markets,” Balto said.
Still, given that Rite Aid has been struggling to compete with other pharmacy retail giants, an argument can be made that its merger deal will actually boost competition and benefit consumers overall. The outcome of the review process could be a sign that antitrust regulators under President Donald Trump will be more open to such “efficiency” arguments than they were during the previous administration, according to Balto.
The deal remains subject to other “customary” closing conditions, including a vote by Rite Aid’s stockholders, the company said.
“The expiration of the HSR waiting period is an important step toward completing the proposed transaction with Albertsons which will create a truly differentiated leader in food, health and wellness to meet the evolving needs of customers,” Rite Aid Chairman and Chief Executive Officer John Standley said in a statement.
To contact the reporter on this story: Alexei Alexis in Washington at email@example.com
To contact the editor responsible for this story: Fawn Johnson at firstname.lastname@example.org
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)